Erasca Faces Securities Fraud Lawsuits
Analysis based on 323 articles · First reported May 19, 2026 · Last updated Jul 19, 2026
The multiple class action lawsuits against Erasca, alleging securities fraud and intellectual property disputes, have severely impacted the company's stock price, causing a significant decline in market capitalization. This event creates uncertainty for investors in the biotechnology sector, particularly those invested in companies with drug candidates in clinical trials, highlighting the importance of transparent and accurate preclinical data reporting.
Erasca, a precision oncology company, is facing multiple class action lawsuits from various law firms including Bronstein, Gewirtz & Grossman, LLC, Kahn Swick & Foti, Hagens Berman, Pomerantz LLP, Robbins Geller Rudman & Dowd LLP, Rosen Law Firm, The Schall Law Firm, Kirby McInerney LLP, and Glancy Prongay & Murray. These lawsuits allege that Erasca made false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, between January 14, 2025, and April 26, 2026. Specifically, the complaints claim that Erasca's preclinical data for ERAS-0015 was based on improper comparisons to Revolution Medicines' RMC-6236, potentially violating patent and trade secret protections. Furthermore, Erasca allegedly lacked a reasonable basis for its positive statements about ERAS-0015. The situation escalated when Erasca disclosed receiving a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, followed by the revelation of a patient's death after receiving ERAS-0015. These disclosures led to a substantial drop in Erasca's stock price, wiping out over $2.8 billion in market capitalization.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard